Safety was consistent with that observed in the plaque psoriasis trials, which Novartis said affirmed Cosentyxs differentiated safety profile. Oct 31: J&J has new competition in the inflammatory disease space after the FDA approved Amgens Wezlana (ustekinumab-auub) for multiple such conditions
Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA
Hims uses asynchronous provider review
The official website describes ingredients including "Pure Gelatine," "Turmeric," and "Burned Berberine" as key components of the formula
Although formal trial data is not yet published, anecdotal outcomes from such clinical use are encouraging
What to look for: A practice that tracks more than scale weight